Clinical Trials Logo

Clinical Trial Summary

This study is a prospective, single-arm, phase II clinical study to evaluate the efficacy and safety of Tislelizumab Plus Chemotherapy in patients with squamous NSCLC with brain metastases who had not previously received systemic therapy.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT05207904
Study type Interventional
Source Sun Yat-sen University
Contact Likun Chen, Ph.D
Phone 13798019964
Email [email protected]
Status Recruiting
Phase Phase 2
Start date June 17, 2021
Completion date June 30, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT04474925 - Pre- Versus Post-operative SRS for Resectable Brain Metastases Phase 3
Recruiting NCT05358340 - Dual Perfusion Imaging for Characterizing Vascular Architecture of Brain Lesions N/A
Not yet recruiting NCT03613181 - ANG1005 in Leptomeningeal Disease From Breast Cancer Phase 3
Completed NCT02082587 - Toronto BNB Pilot Study N/A
Terminated NCT01551680 - A Trial Evaluating Concurrent Whole Brain Radiotherapy and Iniparib in Multiple Non Operable Brain Metastases Phase 1
Terminated NCT00717275 - Study of Temozolomide to Treat Newly Diagnosed Brain Metastases Phase 2
Recruiting NCT03714243 - Blood Brain Barrier Disruption (BBBD) Using MRgFUS in the Treatment of Her2-positive Breast Cancer Brain Metastases N/A
Recruiting NCT04899908 - Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases Phase 2
Recruiting NCT04170777 - Perfexion Registration Using CBCT
Not yet recruiting NCT04507217 - Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous NSCLC Phase 2
Recruiting NCT04582968 - Pyrotinib Combined With Brain Radiotherapy in Breast Cancer Patients With Brain Metastases Phase 1/Phase 2
Recruiting NCT03027544 - Tomotherapy for Refractory Brain Metastases N/A
Completed NCT04178330 - Tomotherapy as Primary Radiotherapy for Multipule Brain Metastases N/A
Terminated NCT02187822 - Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases Phase 1
Recruiting NCT04246879 - MRI Following Stereotactic Radiosurgery (SRS) for Brain Metastases N/A
Active, not recruiting NCT03653546 - First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases Phase 2/Phase 3
Active, not recruiting NCT04410133 - Study to Establish the Diagnostic Performance of 18F Fluciclovine PET in Detecting Recurrent Brain Metastases Phase 3
Terminated NCT04040400 - Study of Intraoperative Radiotherapy for Patients With Large Brain Metastases Treated With Neurosurgical Resection N/A
Recruiting NCT04115254 - Stereotactic Magnetic Resonance Guided Radiation Therapy N/A
Recruiting NCT04824079 - Keynatinib in Treated Patients With NSCLC and Brain Metastases Phase 2